The chemotherapeutic drug resistance of breast CSCs (SUM190) could be mitigated by cardamonin that effectively reduced the activation of NF-κB/IκBα and STAT3, an essential determinant of drug resistance in BC. This evidence concerns the gene NFKB1 and breast cancer.